Strategies of targeting CK2 in drug discovery: challenges, opportunities, and emerging prospects

Y Chen, Y Wang, J Wang, Z Zhou, S Cao… - Journal of Medicinal …, 2023 - ACS Publications
CK2 (casein kinase 2) is a serine/threonine protein kinase that is ubiquitous in eukaryotic
cells and plays important roles in a variety of cellular functions, including cell growth …

Target protein degradation by protacs: A budding cancer treatment strategy

D Choudhary, A Kaur, P Singh, G Chaudhary… - Pharmacology & …, 2023 - Elsevier
Cancer is one of the most common causes of death. So, its lethal effect increases with time.
Near about hundreds of cancers are known in humans. Cancer treatment is done to cure or …

Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives

J Hu, D Zhang, K Tian, C Ren, H Li, C Lin… - European Journal of …, 2023 - Elsevier
Leucine-rich repeat kinase 2 (LRRK2) is a multifunctional protein that orchestrates a diverse
array of cellular processes, including vesicle transport, autophagy, lysosome degradation …

Designing drugs and chemical probes with the dualsteric approach

J Zha, J He, C Wu, M Zhang, X Liu… - Chemical Society Reviews, 2023 - pubs.rsc.org
Traditionally, drugs are monovalent, targeting only one site on the protein surface. This
includes orthosteric and allosteric drugs, which bind the protein at orthosteric and allosteric …

Zooming in on common immune evasion mechanisms of pathogens in phagolysosomes: potential broad-spectrum therapeutic targets against infectious diseases

A Selvapandiyan, N Puri, P Kumar… - FEMS Microbiology …, 2023 - academic.oup.com
The intracellular viral, bacterial, or parasitic pathogens evade the host immune challenges to
propagate and cause fatal diseases. The microbes overpower host immunity at various …

Master kinase PDK1 in tumorigenesis

N Zheng, J Wei, D Wu, Y Xu, J Guo - … et Biophysica Acta (BBA)-Reviews on …, 2023 - Elsevier
phosphoinositide-dependent protein kinase 1 (PDK1) is considered as master kinase
regulating AGC kinase family members such as AKT, SGK, PLK, S6K and RSK. Although …

Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets

A Mushtaq, P Wu, MM Naseer - Pharmacology & Therapeutics, 2023 - Elsevier
Cancer, a noncommunicable disease, is the leading cause of mortality worldwide and is
anticipated to rise by 75% in the next two decades, reaching approximately 25 million cases …

Development and therapeutic potential of adaptor-associated kinase 1 inhibitors in human multifaceted diseases

X Xin, Y Wang, L Zhang, D Zhang, L Sha, Z Zhu… - European Journal of …, 2023 - Elsevier
Abstract Adaptor-Associated Kinase 1 (AAK1), a Ser/Thr protein kinase, responsible for
regulating clathrin-mediated endocytosis, is ubiquitous in the central nervous system (CNS) …

A new wave of innovations within the DNA damage response

Q Li, W Qian, Y Zhang, L Hu, S Chen… - Signal Transduction and …, 2023 - nature.com
Genome instability has been identified as one of the enabling hallmarks in cancer. DNA
damage response (DDR) network is responsible for maintenance of genome integrity in …

Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer

JM Stafford, MD Wyatt, C McInnes - Expert Opinion on Drug …, 2023 - Taylor & Francis
ABSTRACT Introduction Polo Like Kinase 1 (PLK1) is a key regulator of mitosis and its
overexpression is frequently observed in a wide variety of human cancers, while often being …